Global law firm White & Case has advised Recordati S.p.A., a European pharmaceutical group listed on the Italian Stock Exchange, in connection with €100 million term facilities provided by Intesa Sanpaolo S.p.A. and Deutsche Bank AG for the acquisition by its subsidiary, Recordati Rare Diseases Inc. of assets for the treatment of rare diseases and other diseases from Lundbeck LLC. The facilities were guaranteed by Italian parent company Recordati S.p.A. and granted to its subsidiary Recordati Rare Diseases Inc., as borrower.
The White & Case team was led by partners Michael Immordino (Milan/London), Nicholas Lasagna (Milan) and Ferigo Foscari (Milan).
